Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Comparison of NMTCuff and Standard TOF in Gynecologic Oncology Surgery (NMTCUFF-TOF)

3 de novembro de 2026 atualizado por: özge cihangir özek, Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital

Comparison of Neuromuscular Blockade Monitoring Methods in Gynecologic Oncology Surgery: NMTCuff (Vision Duo) Versus Standard Train-of-Four (Acceleromyography)

The use of neuromuscular blocking (NMB) agents in modern anesthesia is essential for optimizing surgical exposure and ensuring patient safety. Inadequate neuromuscular recovery at the end of surgery, known as residual curarization, poses significant risks for critical postoperative respiratory complications, aspiration pneumonia, and prolonged recovery times. Therefore, objective neuromuscular monitoring is strongly recommended by international guidelines, including the American Society of Anesthesiologists (ASA) and the European Society of Anaesthesiology and Intensive Care (ESAIC).

In gynecologic oncology surgery, laparoscopic and robotic approaches often require deep neuromuscular blockade (Post-Tetany Count 1-2) to improve abdominal exposure and allow surgeons to work at lower intraperitoneal pressures. However, the extreme Trendelenburg position and the "tucked-in" positioning of the arms under surgical drapes limit the feasibility of traditional acceleromyography (AMG) monitoring methods. Since AMG devices require free movement of the thumb (m. adductor pollicis), they can yield false-positive or unreliable results when the arms are inaccessible, forcing clinicians to rely on subjective monitoring.

The NMTCuff technology, used by the Vision Duo monitor, measures the neuromuscular response via the contraction pressure of the upper arm muscles (m. triceps/biceps brachii) rather than the wrist. Literature indicates that the response of upper arm muscles correlates better with the diaphragm and laryngeal muscles regarding NMB sensitivity compared to the wrist. This feature suggests that the Vision Duo might detect the recovery of respiratory functions earlier and more reliably.

This study aims to evaluate the correlation and time differences in Train-of-Four (TOF) ratios between the NMTCuff and standard AMG methods during gynecologic oncology surgery. Additionally, it will assess the ease of setup and signal continuity of both devices when the patient's arms remain covered under surgical drapes.

This study is purely prospective and observational in terms of clinical management. The neuromuscular monitoring methods used will not interfere with routine anesthesia care, drug dosing, muscle relaxant reversal strategies, or extubation decisions. The clinician performing the anesthesia management will follow the institutional routine protocol, and data from both devices will only be recorded simultaneously and matched for statistical comparison.

Visão geral do estudo

Status

Recrutamento

Condições

Intervenção / Tratamento

Descrição detalhada

Following approval from the institutional non-interventional clinical research ethics committee and obtaining written and verbal informed consent from all participating patients, this prospective study will be conducted on patients scheduled for elective laparoscopic gynecologic oncology surgery. Patients aged 18-75 years with an American Society of Anesthesiologists (ASA) physical status of I-III will be included. Exclusion criteria consist of a known history of neuromuscular disease, severe hepatic or renal insufficiency, a Body Mass Index (BMI) greater than 35 kg/m2, and patient refusal to participate.

Upon arrival in the operating room, standard monitoring will be applied to all patients, including electrocardiography (ECG), peripheral oxygen saturation (SpO2), and non-invasive blood pressure (NIBP). Anesthesia induction will follow a standardized routine institutional protocol: propofol 2-3 mg/kg, remifentanil 0.5-1 mcg/kg, and rocuronium 0.6 mg/kg to facilitate endotracheal intubation and induce neuromuscular blockade.

Simultaneously, two different neuromuscular monitoring methods will be applied to each patient as follows:

Group 1 - NMTCuff (Vision Duo): Measurements will be performed using a specialized NMT cuff belonging to the Vision Duo monitor. This cuff is placed around the patient's non-dominant upper arm, and neuromuscular transmission is assessed via pressure-sensitive sensors during muscle contraction.

Group 2 - AMG (Standard TOF): Measurements will be performed using a standard acceleromyography (AMG) Train-of-Four (TOF) sensor attached to the contralateral wrist along the ulnar nerve pathway.

At the end of the surgical procedure, routine reversal of the neuromuscular blockade will be performed using Sugammadex at a dose of 2 mg/kg. The recovery times-specifically the duration from the exact moment of Sugammadex administration until the TOF ratio reaches 90% and 100% (matching the Vision Duo Auto-Pilot specification)-will be recorded separately for both devices using a digital stopwatch. Clinical assessment parameters at the time of extubation, including tidal volume and the 5-second head lift test, will also be documented.

This study is purely prospective and observational regarding clinical anesthesia management. The alternative monitoring methods will not intervene in or alter the routine anesthesia care, muscle relaxant dosages, reversal strategies, or extubation decisions. The attending clinician will manage the patient according to the standard operating room practices, and data from both devices will only be recorded simultaneously and matched for subsequent statistical analysis.

Tipo de estudo

Observacional

Inscrição (Estimado)

45

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

Estude backup de contato

Locais de estudo

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos a 75 anos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Fêmea

Método de amostragem

Amostra Não Probabilística

População do estudo

Patients aged 18-75 years with an ASA status of I-III who are scheduled to undergo elective laparoscopic gynecologic oncology surgery at Dr. Abdurrahman Yurtarslan Oncology Training and Research Hospital.

Descrição

Inclusion Criteria:

  • Patients scheduled for elective laparoscopic gynecologic oncology surgery
  • Aged between 18 and 75 years
  • American Society of Anesthesiologists (ASA) physical status I-III
  • Patients who provide written and verbal informed consent

Exclusion Criteria:

  • Known history of neuromuscular disease
  • Severe hepatic or renal insufficiency
  • Body Mass Index (BMI) greater than 35 kg/m2
  • Patient refusal to participate

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Modelos de observação: COHORT
  • Perspectivas de Tempo: PROSPECTIVE

Coortes e Intervenções

Grupo / Coorte
Intervenção / Tratamento
Simultaneous Dual NMT Cohort

A single cohort of patients where each patient receives two different neuromuscular transmission (NMT) monitoring methods simultaneously on opposite arms during elective laparoscopic gynecologic oncology surgery.

Simultaneous recording and matching of data from two different neuromuscular monitoring devices: NMTCuff (Vision Duo) utilizing pressure-sensitive sensors on the non-dominant upper arm, and standard Acceleromyography (AMG) on the contralateral wrist. This monitoring is part of the standard routine anesthesia care and does not interfere with clinical decisions.

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Time to Neuromuscular Recovery (TOF Ratio >= 0.90)
Prazo: From the exact moment of Sugammadex administration up to endotracheal extubation (approximately 10 to 20 minutes).

The time interval (measured in minutes) from the exact moment of the neuromuscular blockade reversal agent (Sugammadex 2 mg/kg) administration until the Train-of-Four (TOF) ratio reaches 90%. This recovery time will be tracked and recorded simultaneously for both the NMTCuff (Vision Duo) and the standard acceleromyography (AMG) devices using a digital stopwatch to evaluate the limits and correlation between the two monitoring methods.

From the exact moment of Sugammadex administration up to endotracheal extubation (approximately 10 to 20 minutes).

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Technical Feasibility and Signal Continuity Under Surgical Drapes
Prazo: From the initiation of anesthesia monitoring in the operating room until the end of the surgical procedure (up to 4 hours).

Evaluation of device installation ease, maintenance of stable sensor connections, and the frequency/duration of any signal loss during the operation. This measure assesses the clinical utility of both devices specifically when the patient's arms are tucked-in along their sides and completely covered under surgical drapes in the extreme Trendelenburg position.

From the initiation of anesthesia monitoring in the operating room until the end of the surgical procedure (up to 4 hours).

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Investigadores

  • Investigador principal: Özge Cihangir Özek, MD, Abdurrahman YAOTRH

Publicações e links úteis

A pessoa responsável por inserir informações sobre o estudo fornece voluntariamente essas publicações. Estes podem ser sobre qualquer coisa relacionada ao estudo.

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

1 de setembro de 2026

Conclusão Primária (Real)

1 de novembro de 2026

Conclusão do estudo (Estimado)

30 de novembro de 2026

Datas de inscrição no estudo

Enviado pela primeira vez

3 de novembro de 2026

Enviado pela primeira vez que atendeu aos critérios de CQ

3 de novembro de 2026

Primeira postagem (Real)

9 de novembro de 2026

Atualizações de registro de estudo

Última Atualização Postada (Real)

9 de novembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

3 de novembro de 2026

Última verificação

1 de novembro de 2026

Mais Informações

Termos relacionados a este estudo

Outros números de identificação do estudo

  • 2026-06/129

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

NÃO

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .